San Diego, CA -- (SBWIRE) -- 05/16/2017 -- Certain directors of Sunesis Pharmaceuticals, Inc. are under investigation concerning possible wrongdoing. The investigation was announced for investors in NASDAQ:SNSS shares over potential breaches of fiduciary duties by certain directors at Sunesis Pharmaceuticals, Inc.

Investors who purchased shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain Sunesis Pharmaceuticals officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Sunesis Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $3.06 million in 2015 to $2.54 million in 2016 and that its respective Net Loss increased from $36.68 million to $38.02 million.

On May 2, 2017, Sunesis Pharmaceuticals, Inc. announced that it will withdraw its European Marketing Authorization Application for vosaroxin, its proposed treatment for relapsed/refractory AML. Sunesis Pharmaceuticals, Inc. conveyed to shareholders that its decision followed recent interactions with the European Medicine Agency's Committee for Medicinal Products for Human Use, in which it learned that the committee was likely to formally adopt a negative opinion in its evaluation of the product.

Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) declined on May 3, 2017 to $2.82 per share.

On May 15, 2017, NASDAQ:SNS shares closed at $3.10 per share.

Those who purchased shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com